医渡科技 1 月通讯丨2024 年

Yidu Tech Events in January 2024

业务进展

Business Progress

医渡云药物临床试验加速平台通过北京市科委和中关村管委会验收

Yidu Cloud's Drug Clinical Trial Acceleration Platform Approved by Beijing Municipal Science & Technology Commission and Administrative Commission of Zhongguancun Science Park

由医渡科技旗下医渡云牵头的"大数据与 AI 驱动的药物临床试验加速平台研发"项目成功通过北京市科委和中关村管委会的验收。平台已在北京大学肿瘤医院、首都医科大学附属北京中医医院、中国中医科学院西苑医院、首都医科大学附属北京友谊医院部署与应用，实现临床试验显著降本增效。

The "Big Data and AI-Driven Drug Clinical Trial Acceleration Platform" project, spearheaded by Yidu Tech's Yidu Cloud, has successfully passed the evaluation by the Beijing Municipal Science & Technology Commission and Administrative Commission of Zhongguancun Science Park. The platform is now deployed and operational at Beijing Cancer Hospital, Capital Medical University Affiliated Beijing Hospital of Traditional Chinese Medicine, Xiyuan Hospital of China Academy of Chinese Medical Sciences (CACMS), and Capital Medical University Affiliated Beijing Friendship Hospital, achieving significant cost reduction and efficiency improvements in clinical trials.

医渡云助力东北首家"慢性进展期肝病数字化管理（CDM）中心"启用

Yidu Cloud Supports the Launch of Northeast China's First "Chronic Advanced Liver Disease Digital Management (CDM) Center"

东北地区首家慢性进展期肝病数字化管理（CDM）中心在沈阳市揭牌启用。作为 CDM 中心的信息技术支持单位，医渡云以人工智能及大数据技术辅助肝脏疾病的全程管理及规范化诊疗，共同为提升慢性进展期肝病患者的诊疗效果和生活质量贡献力量。

The first Chronic advanced liver disease Digital Management (CDM) Center in Northeast China has been inaugurated in Shenyang City. As the IT support entity for the CDM Center, Yidu Cloud employs artificial intelligence and big data technologies to assist in the comprehensive management and standardized treatment of liver diseases, contributing to the enhancement of diagnostic and treatment outcomes and the quality of life for patients with chronic advanced liver disease.

医渡云中标潮州市市域医疗集团信息化平台（一期）项目

Yidu Cloud Secures the Bid for Chaozhou City Medical Group Information Platform (Phase I) Project

医渡云中标潮州市市域医疗集团信息化平台（一期）项目，项目总金额约为人民币 4366 万元。

Yidu Cloud has won the contract for the Chaozhou City Medical Group Information Platform (Phase I) project, with a total project value of approximately RMB 43.66 million.

医渡云中标江苏省某县级市标准体系与数据深度治理项目

Yidu Cloud Wins Bid for a County-Level City Standard System and Data Governance Project in Jiangsu Province

医渡云将利用云计算、大数据、人工智能等新一代信息技术，助力该地构建具有"要素汇聚、治理合规、标准统一、应用开放"特性的区域级智慧医疗大数据基座，打造具有区域本地特色的健康医疗数据要素资产标准体系，推动健康医疗数据采集、治理、应用及安全管理，有效支撑区域内的健康医疗数据实现"数据资源汇聚一个湖、数据要素管理一张图、数据分析利用一平台"的建设目标，激活数据要素潜能。

Yidu Cloud will leverage cloud computing, big data, artificial intelligence, and other next-generation information technologies to assist the area in building a regional-level smart healthcare big data base characterized by "element aggregation, governance compliance, unified standards, and open applications." It aims to establish a regional health and medical data element asset standard system with local characteristics, promote the collection, governance, application, and security management of health and medical data, and effectively support the construction goals of integrating data resources into one lake, managing data elements in one map, and utilizing data analysis on one platform, activating the potential of data elements of regional health and medical data.

医渡云中标西南地区某头部三甲医院临床研究一体化信息系统（一期）项目

Yidu Cloud Wins Bid for Developing an Integrated Clinical Research Information System (Phase I) Project for a Top-tier Third-Class Hospital in Southwest China

医渡云将助力该院打造专业的临床研究一体化信息系统，解决科研数据分散、数据不完整、手工执行效率低质量差等难题，为临床研究全流程提供标准化、电子化支撑，助力提升科研工作效率，促进科研工作成果转化。

Yidu Cloud will assist the hospital in building a specialized integrated clinical research information system, addressing issues such as dispersed research data, incomplete data, low manual execution efficiency and poor quality. It provides standardized, digitalized support for the entire clinical research process, enhancing research efficiency and facilitating the transformation of research findings.

HLT 高效助力 PIONEER 研究重要里程碑达成

HLT Efficiently Facilitates a Significant Milestone in the PIONEER Study

在医渡科技旗下开心生活科技(HLT)的协助下，PIONEER 研究项目入组工作已圆满完成，标志着该研究已进入关键阶段。该项目由广州医科大学附属第一医院/广州呼吸健康研究院/国家呼吸医学中心/国家呼吸系统疾病临床医学研究中心发起，国家呼吸系统疾病临床医学研究中心主任钟南山院士担任牵头研究者，全国 21 家研究机构共同参与，阿斯利康投资(中国)有限公司支持并提供研究药物，HLT 在该项目中负责整个项目的临床运营、数据管理和药物警戒（PV）服务，以及临床试验研究协调员服务，协助研究者完成临床试验，保证项目进度与质量。

With support from Happy Life Technology (HLT), a subsidiary of Yidu Tech, the enrollment phase of the PIONEER study has been successfully completed, marking the entry into a critical phase of the study. Initiated by the First Affiliated Hospital of

Guangzhou Medical University/Guangzhou Institute of Respiratory Health/National Respiratory Medical Center/National Clinical Research Center for Respiratory Diseases, with Director of the National Clinical Medical Research Center for Respiratory Diseases, Academician Zhong Nanshan as the lead researcher and participation from 21 research institutions nationwide. Supported by AstraZeneca Investment (China) Co., Ltd., which provided the research drug, HLT was responsible for the entire project's clinical operations, data management, pharmacovigilance (PV) services, and clinical trial research coordinator services, assisting researchers in completing clinical trials, ensuring project progress and quality.

HLT 助力华润生物 1 类创新药Ⅰ期临床试验圆满完成

HLT Supports Successful Completion of Phase I Clinical Trial for the Class I Innovative Drug by China Resources Biopharmaceutical

由华润生物医药有限公司开发、HLT 提供临床研究服务的 CRB4101 药物Ⅰ期临床试验项目圆满结束，该试验证实了 CRB4101 片在健康成人中的良好安全性和耐受性，为其后续研发和临床应用奠定了坚实的基础。HLT 从试验项目的启动阶段就积极参与，为项目方案制定、研究中心立项、伦理审查等环节提供了支持。在临床运营、数据管理和分析方面，HLT 提供高效、专业的服务，确保临床试验数据的可靠性和高质量。

The Phase I clinical trial project of CRB4101, developed by China Resources Biopharmaceutical Co., Ltd. and serviced by HLT for clinical research, has successfully concluded. This trial confirmed the good safety and tolerability of CRB4101 tablets in healthy adults, laying a solid foundation for its further development and clinical application. HLT has been actively involved since the trial's initiation phase, providing support for project planning, research center establishment, and ethical review. In clinical operations, data management, and analysis, HLT provided efficient and professional services to ensure the reliability and high quality of clinical trial data.

HLT 中标某眼科创新药企 2 类新药 I 期项目

HLT Wins Bid for a Phase I Project for a Class II Innovative Drug by an Ophthalmology Pharmaceutical Company

该客户为潜在患者提供了创新的疾病治疗选择，具有广阔的市场前景，HLT 将为其提供医学撰写、临床运营、数统服务等完整解决方案。HLT 以眼科领域的高度专业性，获得客户的认可和肯定，将尽快推进相关工作，助力产品的研发进程。

The client offers innovative treatment options for potential patients with broad market prospects. HLT will provide complete solutions including medical writing, clinical operations, and biostatistics services. With its high professionalism in the ophthalmology field, HLT has been recognized and affirmed by the client, and will expedite related work to support the product's research and development process.

因数云主运营的北京、江苏惠民保参保再创新高

CausaCloud's Main Operation of Beijing and Jiangsu Hui Min Bao Reaches New Record Highs of Insured Number

2024 年度"北京普惠健康保"、"江苏医惠保 1 号"投保圆满收官。其中，"北京普惠健康保"参保人数突破 423 万，"江苏医惠保 1 号"参保人数突破 517 万，均创历史新高。医渡科技旗下因数云已连续三年担任两个项目的主运营平台。

The 2024 enrollment for "Beijing Supplementary Insurance" and "Jiangsu Supplementary Insurance No. 1" has successfully concluded, with the former surpassing 4.23 million enrollees and the later exceeding 5.17 million, setting new historical records. CausaCloud, a subsidiary of Yidu Tech, has served as the main operating platform for both projects for three consecutive years.

集团荣誉

Honors of Yidu Tech

医渡科技创新实践纳入数字医疗白皮书，并获评年度优秀案例

Yidu Tech's Innovative Practices Featured in Digital Healthcare White Paper and Awarded Annual Excellence Case

动脉网与蛋壳研究院发布《2023 数字医疗年度创新白皮书》，并揭晓年度创新优秀案例。医渡科技在医疗大模型、新一代数据中心、数字疗法等数字医疗领域的创新探索被白皮书收录，并成功获评年度创新优秀案例。

VBdata and VCbeat Research Institute released the "2023 Digital Healthcare Annual Innovation White Paper," unveiling the year's outstanding innovation cases. Yidu Tech's explorations in large language model in the medical vertical field, next-generation data centers, and digital therapeutics within the digital healthcare domain were included in the white paper and successfully recognized as an annual innovation excellence case.

医渡科技获颁"新财富最佳 IR 港股公司"奖

Yidu Tech Awarded "New Fortune Best IR Hong Kong Listed Company" Prize

新财富上市公司可持续发展年会暨第十九届新财富金牌董秘、第六届新财富最佳 IR 港股公司颁奖成功举办，医渡科技获颁"新财富最佳 IR 港股公司（H 股）"奖项。该奖在业内具有较高公信力和影响力，超过 3000 位从事港股研究的券商分析师、QDII 基金/投资经理、香港及海外市场投资机构等投票人参与投票，仅有 20 家公司（H 股）上榜。医渡科技从 322 家候选公司中脱颖而出，彰显了投资者对公司业务发展、管治能力及投资者关系工作的认可。

The New Fortune Listed Company Sustainable Development Annual Conference and

the 19th New Fortune Gold Board Secretary, the 6th New Fortune Best IR Hong Kong Listed Company awards ceremony were successfully held, where Yidu Tech was honored with the "New Fortune Best IR Hong Kong Listed Company (H-shares)" award. This award, highly regarded for its credibility and influence within the industry, saw participation from over 3000 professionals engaged in Hong Kong stock research, including securities analysts, QDII fund/investment managers, and investment institutions from Hong Kong and overseas, with only 20 companies (H-shares) making the list. Yidu Tech stood out among 322 candidate companies, showcasing investor recognition for the company's business development, governance capabilities, and investor relations efforts.

医渡科技荣登"2023 智慧医疗解决方案提供商 TOP50"榜单榜首

Yidu Tech Tops the "2023 Smart Healthcare Solution Providers TOP 50" List

中国科学院《互联网周刊》、德本咨询与 eNet 研究院联合发布了"2023 智慧医疗解决

方案提供商 TOP50"榜单，医渡科技凭借前瞻的医疗智能领域布局、创新的人工智能技术研发、成熟的场景应用以及亮眼的对医疗智能行业发展的贡献度和影响力荣登榜首，获得行业认可。

The "China Internet Week" of the Chinese Academy of Sciences, Deben Consulting (DBC), and eNet Research Institute jointly released the "2023 Smart Healthcare Solution Providers TOP50" list. Yidu Tech, with its forward-looking layout in the medical intelligence field, innovative AI technology development, mature application scenarios, and significant contributions to the development of the medical intelligence industry, secured the top spot on the list and received industry recognition.

医渡科技获评"微博 2023 年度 ESG 新锐影响力企业"

Yidu Tech Named "Weibo 2023 ESG Emerging Influence Enterprise"

微博 ESG 与可持续发展论坛在京举行，论坛揭晓了"2023 年度 ESG 新锐影响力企业"奖项。医渡科技作为中国医疗智能行业的头部企业，公司全面贯彻新发展理念，积极推进 ESG 实践，持续受到社会肯定，此次亦成功获得该项殊荣。

The Weibo ESG and Sustainable Development Forum was held in Beijing, where the "2023 ESG Emerging Impact Company" awards were announced. As a leading enterprise in China's healthcare intelligence industry, Yidu Tech has fully implemented new development concepts and actively advanced ESG practices, continuously receiving societal affirmation and successfully earning this prestigious accolade.

医渡科技荣登"2023 年度人工智能创新企业百强榜"前十

Yidu Tech Ranks in the Top Ten of the "2023 Top 100 AI Innovative Enterprises" List

《互联网周刊》、德本咨询与中国社会科学院信息化研究中心联合发布"2023 年度人工智能创新企业 100 强"榜单，这份榜单聚焦于中国各行各业的人工智能领域，着重从创新性、突破性方面对于企业进行评级。医渡科技与百度、阿里巴巴、华为、字节跳动等企业一同进入榜单前十。这是继日前获评"2023 年度卓越人工智能企业"后，医渡科技再次凭借垂类大模型创新获得人工智能领域权威认可。

"China Internet Week," Deben Consulting (DBC), the China Informationization Research Center of Social Sciences (CIS) released the "2023 Top 100 AI Innovative Enterprises" list. This list focuses on the AI field across various industries in China, rating companies based on innovation and breakthroughs. Yidu Tech, alongside companies like Baidu, Alibaba, Huawei, and ByteDance, entered the top ten of the list.

Following its recent recognition as the "2023 Outstanding AI Enterprise," Yidu Tech has once again received authoritative acknowledgment in the AI field for its large language model innovation in the medical vertical field.

因数云主运营的北京、江苏惠民保获评 2023 年多层次医疗保障优秀案例

CausaCloud's Operation of Beijing and Jiangsu Supplementary Insurance Named 2023 Multi-level Medical Security Excellent Case

由医渡科技旗下因数云提供全流程服务支持的惠民保项目"北京普惠健康保"、"江苏医惠保 1 号"成功获评"2023 年多层次医疗保障优秀案例"，这也是两个项目第二次获得该项荣誉。

The Hui Min Bao projects "Beijing Supplementary Insurance" and "Jiangsu Supplementary Insurance No. 1," which are supported by the whole process service provided by CausaCloud, a subsidiary of Yidu Tech, have been awarded the "2023 Multi-level Medical Security Excellent Case." This marks the second time these projects have received this honor.

因数云再度入围分子实验室"中国保险科技 100 强"

CausaCloud Once Again Enters the "INSLAB Top 100 of China InsurTech in 2023"

国内保险科技研究机构"分子实验室"发布了"2023 中国保险科技 100 强"名单，医渡科技旗下因数云凭借突出的科技创新能力、服务能力和卓越的技术能力，再度入围"中国保险科技 100 强"。该榜单经过 2023 年保险科技创新大赛、乌镇保险科技节和两百余位评委的提名推荐，其评选结果在行业内具有极强的公信力和影响力。此次再度入围 100 强，充分彰显了业内对因数云在保险科技领域实力的高度认可。

INSLAB, a domestic insurance tech research institution, released the "Top 100 of

China InsurTech in 2023" list. CausaCloud, a subsidiary of Yidu Tech, was re-selected for the "Top 100 of China InsurTech" by virtue of its outstanding technological innovation capabilities, service capabilities, and exceptional technical proficiency. The selection process involved the 2023 Insurance Technology Innovation Contest, the 2023 Wuzhen Insurance Technology Festival, and nominations from over two hundred judges, making the results highly credible and influential in the industry. This re-inclusion in the top 100 highlights the high recognition CausaCloud receives in the insurance tech field from the industry.

资本市场动态

IR Market Dynamics

医渡科技获管理层自愿买入 35 万股公司股份

Yidu Tech Executive Voluntarily Purchases 350,000 Shares of the Company

据公开信息，医渡科技执行董事、CFO 封晓瑛女士于 2024 年 1 月 11 日至 1 月 12 日在公开市场上购入 35 万股公司股份，总金额约为 150 万港元，体现了对医渡科技发展前景和长期投资价值的认可。

在医渡科技 2024 财年中期业绩发布会上，公司管理层就曾指出，"即便非常保守计算，仅基于国际业务的最新估值和公司的重要资产储备，不考虑任何国内业务，公司每股价值也比近 60 日均价（4.09 港元/股）高出 50%左右。"因此，管理层认为医渡科技的股价被严重低估。

According to publicly available information, Ms. Feng Xiaoying, Executive Director and CFO of Yidu Tech (2158.HK), purchased 350,000 shares of the company on the public stock market from January 11 to January 12, 2024, for a total amount of approximately 1.5 million Hong Kong dollars, which reflects the recognition of Yidu Tech's

development prospects and long-term investment value.

At the Fiscal Year 2024 Interim Results Announcement Conference, the company's management pointed out that "even with a very conservative calculation, based solely on the latest valuation of the international business and the company's significant asset reserves, and didn't take any domestic business into consideration, the 'value' per share is about 50% higher than the recent 60-day average market price (4.09 HKD per share)." Therefore, the management believes that Yidu Tech's stock price is severely undervalued.

国联证券发布报告提及医渡科技

Guolian Securities Releases Report Mentioning Yidu Tech

国联证券发布《计算机：AIGC 产业链近况更新》报告，指出国内大模型日益成熟，提及医渡科技近期发布自主研发的医疗垂域大模型，在分导诊、基础医学、全科医学、临床内科、临床外科、执业资格考试等多个医疗明确任务场景上的评测表现已经超过 GPT3.5，将赋能城市级医疗资源综合监管、传染病监测预警与应急处置以及 C 端健康服务等多个场景。在 AI 应用的垂直领域，国联证券建议关注医渡科技。

Guolian Securities published a report titled "Computers: Update on the AIGC Industry Chain," noting the increasing maturity of domestic large language models. The report mentions Yidu Tech's recent release of its proprietary large language model in the medical vertical field which have surpassed the performance of GPT3.5 in several specific medical task scenarios, including hospital triage and guide, basic medicine, general medicine, clinical internal medicine, clinical surgery, and professional qualification exams, empowering comprehensive supervision of urban medical resources, infectious disease monitoring and emergency response, as well as C-end health services. In the vertical field of AI applications, Guolian Securities recommends paying attention to Yidu Tech.